Antibody Isotypes for Tumor Immunotherapy

Human Secretory IgM Antibodies Activate Human Complement and Offer Protection at Mucosal Surface

(2017) T. E. Michaelsen et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity

(2017) Tim Wirt et al.   TRANSFUSION MEDICINE AND HEMOTHERAPY

Influence of immunoglobulin isotype on therapeutic antibody function

(2016) Stephen A. Beers et al.   BLOOD

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency

(2016) Stylianos Bournazos et al.   CELL

Antibodies to watch in 2017

(2016) Janice M. Reichert   mAbs

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

(2015) Ann L. White et al.   CANCER CELL

An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo

(2015) Stefan Lohse et al.   CANCER RESEARCH

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6

(2015) L. Rasche et al.   HAEMATOLOGICA

A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA

(2015) Gerard JA Rouwendal et al.   mAbs

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6

(2015) L. Rasche et al.   HAEMATOLOGICA

Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro

(2015) Jennifer D. Könitzer et al.   PLoS One

The Long Elusive IgM Fc Receptor, FcμR

(2014) Hiromi Kubagawa et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Epidermal Growth Factor Receptor Targeting IgG3 Triggers Complement-Mediated Lysis of Decay-Accelerating Factor Expressing Tumor Cells through the Alternative Pathway Amplification Loop

(2014) T. Rosner et al.   JOURNAL OF IMMUNOLOGY

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

(2014) Timothy J Price et al.   LANCET ONCOLOGY

Opening the door to innovation

(2014) Janine Schuurman et al.   mAbs

Fc Receptors for Immunoglobulins and Their Appearance during Vertebrate Evolution

(2014) Srinivas Akula et al.   PLoS One

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels

(2013) Thies Rösner et al.   BRITISH JOURNAL OF HAEMATOLOGY

IgAEGFR antibodies mediate tumour killingin vivo

(2013) Peter Boross et al.   EMBO Molecular Medicine

IgE immunotherapy

(2013) Debra H Josephs et al.   mAbs

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

(2013) A. F. Labrijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Isotype and glycoform selection for antibody therapeutics

(2012) Roy Jefferis   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

Crosstalk between Human IgG Isotypes and Murine Effector Cells

(2012) M. B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Protective Roles of Natural IgM Antibodies

(2012) Caroline Grönwall et al.   Frontiers in Immunology

Structure and function relationships in IgA

(2011) J M Woof et al.   Mucosal Immunology

Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

(2011) Nigel M. Stapleton et al.   Nature Communications

IgG Subclass Profiles in Infected HIV Type 1 Controllers and Chronic Progressors and in Uninfected Recipients of Env Vaccines

(2010) Kaustuv Banerjee et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

(2009) Tanja Schneider-Merck et al.   JOURNAL OF IMMUNOLOGY

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

(2009) Aran F Labrijn et al.   NATURE BIOTECHNOLOGY

Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells

(2008) S. L. Fu et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY